|
시장보고서
상품코드
1973263
Mab 바이오시밀러 시장 규모, 점유율, 성장 분석 : 제품 유형별, 치료 영역별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Mab Biosimilar Market Size, Share, and Growth Analysis, By Product Type (Bevacizumab Biosimilars, Rituximab Biosimilars), By Therapeutic Area, By Application, By End-User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 Mab 바이오시밀러 시장 규모는 2024년에 6억 8,950만 달러로 평가되었고, 2025년 7억 4,259만 달러에서 2033년까지 13억 4,424만 달러로 성장할 전망입니다. 예측 기간(2026-2033년) CAGR은 7.7%를 나타낼 것으로 예측됩니다.
세계 단일클론항체(mAb) 바이오시밀러 시장은 오리지널 의약품의 특허 만료와 비용 효율적이고 임상적으로 동등한 치료법에 대한 수요 증가로 인해 크게 성장하고 있습니다. 복잡한 단백질 의약품의 거의 동일한 복제품인 이들 제품은 단클론 항체가 가장 비싼 의약품 중 하나이기 때문에 종양학, 면역학, 희귀질환 치료에 필수적입니다. 규제의 명확화와 확장 가능한 제조 방법의 출현으로 시장 진입이 용이해져 가격 인하와 환자 접근성 확대가 촉진되고 있습니다. 성공적인 바이오시밀러 입찰 과정으로 대표되는 경쟁의 격화는 임상의들이 보다 저렴한 대안으로 전환하도록 유도하고 있습니다. 또한, 개발 단계에서의 인공지능 통합은 설계 최적화, 예측 가능성 향상, 개발 기간 단축을 통해 효율성을 높이고, 궁극적으로 시장 진입을 가속화하고 이 분야에서 지속 가능한 세계 성장을 가능하게 합니다.
세계 mAb 바이오시밀러 시장 활성화 요인
세계 mAb 바이오시밀러 시장의 성장은 환자들이 직면한 경제적, 물류적 문제를 완화하기 위한 환자 접근성 프로그램의 확대 시행으로 인해 크게 촉진되고 있습니다. 제조업체는 본인 부담금 지원, 의료 시스템 탐색, 환자와 처방자 모두에 대한 교육을 제공함으로써 더 많은 사람들이 이러한 치료법에 접근할 수 있도록 돕고 있습니다. 이러한 노력은 의료 서비스 제공업체 간의 신뢰를 구축하고, 치료의 연속성을 촉진하며, 궁극적으로 바이오시밀러의 대체 및 반복 처방으로 이어질 수 있습니다. 또한, 제조업체, 의료 제공업체, 보험사 간의 협력을 통한 접근 경로의 최적화는 시장 침투를 더욱 촉진하고 mAb 바이오시밀러에 대한 지속적인 수요를 창출할 수 있습니다.
세계 mAb 바이오시밀러 시장 성장 억제요인
세계 Mab 바이오시밀러 시장은 복잡한 제조 공정으로 인해 심각한 제약에 직면해 있습니다. 이러한 복잡성은 기술적, 운영적 장벽을 만들고, 개발의 어려움과 생산 위험을 증가시켜 시장 성장을 저해합니다. 세포주, 정제 방법, 품질 기준을 면밀히 관리하기 위해서는 전문 지식과 첨단 시설에 대한 막대한 투자가 필수적입니다. 제조상의 가변성은 비교가능성에 대한 규제 당국의 평가를 더욱 복잡하게 만들고, 생산의 효율적인 확장을 어렵게 만듭니다. 이는 신규 진입을 막고, 생산 능력의 확장을 저해하는 요인으로 작용합니다. 공급 안정성과 제품 품질에 대한 우려로 인해 지불 기관과 공급자는 신중한 조달 결정을 내리기 때문에 보급이 제한되어 있습니다.
세계 mAb 바이오시밀러 시장 동향
세계 mAb 바이오시밀러 시장은 헬스케어 인프라의 개선과 규제 개선이 탄탄한 기회를 창출하고 있는 신흥 시장 확대에 힘입어 괄목할 만한 성장을 거듭하고 있습니다. 각 제조업체들은 다양한 상환 시나리오에 대응하기 위해 현지 파트너십 구축 및 개별 대응형 가격 전략을 적극적으로 추진하여 바이오시밀러에 대한 접근성을 높이고 있습니다. 또한, 타겟별 유통 전략과 지역 이해관계자와의 협업을 통해 제품 포트폴리오의 다양화와 경쟁력 강화를 실현하고 있습니다. 각 기업들은 지속적인 시장 침투를 위해 각 지역의 변화하는 헬스케어 우선순위에 맞추어 문화적으로 적합한 의료진 및 환자 참여 방안을 시행하고 있으며, 이는 궁극적으로 세계 바이오시밀러 시장 수요와 성장을 견인하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 Mab 바이오시밀러 시장 규모 : 제품 유형별&CAGR(2026-2033)
세계의 Mab 바이오시밀러 시장 규모 : 치유 영역별&CAGR(2026-2033)
세계의 Mab 바이오시밀러 시장 규모 : 용도별&CAGR(2026-2033)
세계의 Mab 바이오시밀러 시장 규모 : 최종사용자별&CAGR(2026-2033)
세계의 Mab 바이오시밀러 시장 규모 : 유통 채널별&CAGR(2026-2033)
세계의 Mab 바이오시밀러 시장 규모&CAGR(2026-2033)
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.03.31Global Mab Biosimilar Market size was valued at USD 689.5 Million in 2024 and is poised to grow from USD 742.59 Million in 2025 to USD 1344.24 Million by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).
The global monoclonal antibody (mAb) biosimilar market is witnessing significant growth due to the expiration of original biologic patents and increasing demand for cost-effective, clinically equivalent therapies. These near-identical copies of complex protein drugs are crucial for treating oncology, immunology, and rare diseases, as monoclonal antibodies are among the most expensive medications. As regulatory clarity and scalable manufacturing methods emerge, market entry has become easier, driving price reductions and broader patient access. Increased competition, exemplified by successful biosimilar tender processes, encourages clinicians to switch to more affordable options. Additionally, the integration of artificial intelligence in development enhances efficiency by optimizing design, improving predictability, and accelerating timelines, ultimately enabling faster market entry and sustainable global growth in this sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mab Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Mab Biosimilar Market Segments Analysis
Global mab biosimilar market is segmented by product type, therapeutic area, application, end-user, distribution channel and region. Based on product type, the market is segmented into Bevacizumab Biosimilars, Rituximab Biosimilars, Trastuzumab Biosimilars and Other Monoclonal Antibody Biosimilars. Based on therapeutic area, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases and Other Therapeutic Areas. Based on application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Clinics and Contract Manufacturing Organizations. Based on end-user, the market is segmented into Hospitals, Diagnostic Centers, Research Institutes, Biotechnology & Pharmaceutical Companies and Others. Based on distribution channel, the market is segmented into Direct Sales, Distributors and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Mab Biosimilar Market
The growth of the global mAb biosimilar market is significantly driven by the implementation of expanding patient access programs that aim to alleviate financial and logistical challenges faced by patients. By providing support for co-payments, navigating healthcare systems, and educating both patients and prescribers, manufacturers enhance the accessibility of these therapies to a wider audience. Such initiatives build trust among healthcare providers and facilitate continuity of care, ultimately promoting the substitution and repeated prescription of biosimilars. Additionally, collaboration between manufacturers, providers, and payers to optimize access pathways further boosts market penetration and fosters sustained demand for mAb biosimilars.
Restraints in the Global Mab Biosimilar Market
The global market for monoclonal antibody biosimilars faces significant restraints due to the intricate manufacturing processes involved. These complexities create technical and operational hurdles that hinder market growth, as they increase both development difficulties and production risks. The requirement for meticulous management of cell lines, purification methods, and quality standards necessitates specialized knowledge and substantial investment in advanced facilities. Variability in manufacturing can further complicate regulatory assessments of comparability, making it challenging to scale production effectively, which discourages new market entrants and impedes capacity growth. Concerns surrounding supply consistency and product quality lead to cautious procurement choices by payers and providers, limiting widespread adoption.
Market Trends of the Global Mab Biosimilar Market
The global mAb biosimilar market is experiencing significant growth, driven by the expansion of emerging markets where healthcare infrastructure improvement and regulatory advancements are creating robust opportunities. Manufacturers are actively forming local partnerships and adopting tailored pricing strategies to address varying reimbursement scenarios, enhancing access to biosimilars. Additionally, targeted distribution strategies and collaborative efforts with regional stakeholders facilitate portfolio diversification and strengthen competitive positioning. To ensure sustained market uptake, companies are implementing culturally relevant clinician and patient engagement initiatives that align with the evolving healthcare priorities of these regions, ultimately driving demand and growth in the global biosimilar landscape.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Mab Biosimilar Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Bevacizumab Biosimilars
- Rituximab Biosimilars
- Trastuzumab Biosimilars
- Other Monoclonal Antibody Biosimilars
Global Mab Biosimilar Market Size by Therapeutic Area & CAGR (2026-2033)
- Market Overview
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Respiratory Diseases
- Other Therapeutic Areas
Global Mab Biosimilar Market Size by Application & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Clinics
- Contract Manufacturing Organizations
Global Mab Biosimilar Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Diagnostic Centers
- Research Institutes
- Biotechnology & Pharmaceutical Companies
- Others
Global Mab Biosimilar Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Direct Sales
- Distributors
- Online Pharmacies
Global Mab Biosimilar Market Size & CAGR (2026-2033)
- North America (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
- US
- Canada
- Europe (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celltrion
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EMD Serono
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
